We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Mednax (MD) Down 12.3% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Mednax (MD - Free Report) . Shares have lost about 12.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Mednax due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
MEDNAX Q1 Earnings Miss Estimates, Decline Y/Y
MEDNAX reported first-quarter 2019 adjusted earnings of 65 cents per share, missing the Zacks Consensus Estimate by 8.5%. Moreover, the bottom line decreased 27% year over year due to a rise in expenses and lower revenues.
Quarterly Details
The company generated revenues of $851.18 million, lagging the Zacks Consensus Estimate by 5.9%. Also, the top line was down 0.2% from the year-ago period.
General and administrative expenses inched up 0.1% to $101 million.
Interest expenses of the company escalated 54.3% to $30.7 million, primarily due to higher effective interest rate on borrowings between the two periods.
In the quarter under review, adjusted EBITDA totaled $104.9 million, down by nearly 14.3%.
Financial Update
As of Mar 31, 2019, the company had cash and cash equivalents of about $46.5 million, down 2.2% from the level as of 2018 end.
The company incurred total debt of $2.1 billion, up 7.3% from the level as of Dec 31, 2018, and total assets of $5.7 billion, down 3.9% from the figure at 2018 end.
It used $60.4 million to fund operations in the first three months of 2019, down 48.3% year over year.
Capital Deployment
The company bought back shares worth $79 million in the first three months of 2019.
Second-Quarter Outlook
For the second quarter of 2019, the company expects adjusted EPS in the band of 84-92 cents, up from the previous guidance of 67-75 cents. MEDNAX projects adjusted EBITDA in the range of 125-$135 million, up from the past forecast of $108-$118 million.
This guidance assumes total same-unit revenue growth for the second quarter of 2019 from flat to 2% as compared to the prior-year period’s level.
2019 Guidance Revised
The company now estimates adjusted EBITDA within $505-$535 million, down from the earlier prediction of $550-$580 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -9.42% due to these changes.
VGM Scores
At this time, Mednax has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Mednax has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Mednax (MD) Down 12.3% Since Last Earnings Report?
A month has gone by since the last earnings report for Mednax (MD - Free Report) . Shares have lost about 12.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Mednax due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
MEDNAX Q1 Earnings Miss Estimates, Decline Y/Y
MEDNAX reported first-quarter 2019 adjusted earnings of 65 cents per share, missing the Zacks Consensus Estimate by 8.5%. Moreover, the bottom line decreased 27% year over year due to a rise in expenses and lower revenues.
Quarterly Details
The company generated revenues of $851.18 million, lagging the Zacks Consensus Estimate by 5.9%. Also, the top line was down 0.2% from the year-ago period.
General and administrative expenses inched up 0.1% to $101 million.
Interest expenses of the company escalated 54.3% to $30.7 million, primarily due to higher effective interest rate on borrowings between the two periods.
In the quarter under review, adjusted EBITDA totaled $104.9 million, down by nearly 14.3%.
Financial Update
As of Mar 31, 2019, the company had cash and cash equivalents of about $46.5 million, down 2.2% from the level as of 2018 end.
The company incurred total debt of $2.1 billion, up 7.3% from the level as of Dec 31, 2018, and total assets of $5.7 billion, down 3.9% from the figure at 2018 end.
It used $60.4 million to fund operations in the first three months of 2019, down 48.3% year over year.
Capital Deployment
The company bought back shares worth $79 million in the first three months of 2019.
Second-Quarter Outlook
For the second quarter of 2019, the company expects adjusted EPS in the band of 84-92 cents, up from the previous guidance of 67-75 cents. MEDNAX projects adjusted EBITDA in the range of 125-$135 million, up from the past forecast of $108-$118 million.
This guidance assumes total same-unit revenue growth for the second quarter of 2019 from flat to 2% as compared to the prior-year period’s level.
2019 Guidance Revised
The company now estimates adjusted EBITDA within $505-$535 million, down from the earlier prediction of $550-$580 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -9.42% due to these changes.
VGM Scores
At this time, Mednax has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Mednax has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.